Novo executive on new approval: "Ozempic is unequivocally the strongest product in its class"

Novo Nordisk has gained a clear competitive edge, after the FDA approved the addition of new cardiovascular data to the enclosed information sheet for its diabetes drug Ozempic, believes Novo Nordisk's research director Mads Krogsgaard Thomsen.

Mads Krogsgaard Thomsen, research director at Novo Nordisk. Photo: Jacob Ehrbahn / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles